Losatuxizumab
Losatuxizumab Basic information
- Product Name:
- Losatuxizumab
- Synonyms:
-
- Losatuxizumab
- Research Grade Losatuxizumab(DHB86913)
- Research Grade Losatuxizumab
- Losatuxizumab (anti-EGFR)
- CAS:
- 1801544-27-3
- MW:
- 0
- Mol File:
- Mol File
Losatuxizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Losatuxizumab Usage And Synthesis
Uses
Losatuxizumab is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers[1][2].
in vivo
Lorigerlimab has antitumor activities in various wild-type EGFR-expressing squamous cell carcinoma xenograft model[1].
Lorigerlimab (40 mg/kg, i.p.) significantly inhibits growth of U87MGde2-7 tumor in mice[1].
Lorigerlimab (10 and 40 mg/kg, i.p.) prolongs survival and reduces levels of pEGFR in PDX GBM model (SN0207 tumor)[1].
| Animal Model: | PDX GBM model (SN0207 tumor)[1] |
| Dosage: | 40 mg/kg |
| Administration: | i.p. |
| Result: | Prolonged survival rate, and reduced levels of pEGFR in tumor. |
References
[1] Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. DOI:10.1158/1535-7163.MCT-14-0820
[2] Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9. DOI:10.1158/1535-7163.MCT-15-0901
LosatuxizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com